Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. BICO Group AB (publ)
  6. News
  7. Summary
    BICO   SE0013647385


Real-time Estimate Cboe Europe  -  09:26 2022-09-26 am EDT
28.24 SEK   +2.60%
09/14BICO : Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
08/31PRESS RELEASE : New L version of the I.DOT: Now Available
08/24TRANSCRIPT : BICO Group AB, Q2 2022 Earnings Call, Aug 24, 2022
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BICO : SCIENION announces expansion in the UK with the opening of new R&D and manufacturing facilities

07/28/2022 | 12:57pm EDT

UK to become global hub for contract manufacturing services

Lakeside North Harbour, Portsmouth, UK; July 28, 2022: Together with numerous guests from politics, economics, life sciences and medical diagnostics, SCIENION the precision liquid handling specialist and part of bioconvergence powerhouse BICO,today celebrated the opening of new state of the art facilities in Portsmouth. More than 1,000 square meters will enable SCIENION UK to run customer R&D projects including single cell applications. The new location provides ISO5 clean room facilities for contract manufacturing services to address the rapidly growing UK and worldwide customer base.

SCIENION's UK customer base has significantly expanded over the last 15 years. In order to interact closer with its customer base, SCIENION UK Ltd. was founded in Chichester in 2019 and led to the expansion to new facilities in Portsmouth. SCIENION UK is now able to promote and provide more extensive services and opportunities for collaborations with its UK customers.

Dr Holger Eickhoff, founder and CEO of SCIENION GmbH and BICO SVP & Business Area Bioautomation Director, said: "Despite all Brexit and Covid challenges in recent years we are proud that we could support our important UK customers with our products, services and technologies which are key in modern diagnostic test manufacturing. Having examined a number of possible options, SCIENION is convinced that the new global hub for contract manufacturing in Portsmouth is the best possible for the Group, and will create the highest value for all Stakeholders."

Dr Andrew Sweet, Managing Director of SCIENION UK, Ltd was especially glad to welcome The Lord Mayor of Portsmouth and the Lady Mayoress, Councillor Canon Dr Hugh Mason and Miss Marie Costa and Penny Mordaunt, Member of Parliament, along with guests from the life sciences and medical diagnostics sectors. He said: "It is an honor and great pleasure for us to jointly celebrate with you the opening of our new facilities. Here at Lakeside North Harbour, we now have the facilities, personnel and equipment to enable, inspire and educate customers to develop their research projects through to full scale manufacturing. Further to be able to participate in the extraordinary innovations in cancer research being advanced by UK pharmaceutical and academic institutions."

Penny Mourdant, Member of Parliament for Portsmouth North, said: "It is exciting to see SCIENION bring their technologies, services, and contract manufacturing capabilities to Portsmouth. As a Government, we strongly support the sector and have a bold life sciences vision to work with companies like SCIENION to bring innovative solutions to the healthcare challenges of our time."

As the UK hub for the BICO group, SCIENION and sister companies will be utilizing the new premises to showcase their capabilities and expertise in the bioautomation, bioprinting and biosciences arenas, forging key collaborations with scientists, academics and industrial partners.


Founded in 2001, SCIENION is a renowned specialist in ultra-low volume precision liquid handling in the pico-liter to micro-liter range, enabling applications from research to high-throughput production of assays in diagnostics and life sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION is an ISO 9001:2015 certified complete solution provider offering a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing services. The company operates from two sites in Germany, Berlin and Dortmund, and has subsidiaries in Phoenix, Arizona (USA), Portsmouth (UK), and Lyon (France). The French subsidiary Cellenion offers solutions for single cell analyses, e.g. with the single cell dispenser cellenONE and products such as cellenCHIP and proteoCHIP for omics-based applications.

SCIENION is part of BICO, the leading bio convergence company in the world that provides technologies, products and services to create the future of health.

About BICO

Founded in 2016, BICO (formerly CELLINK) is the world's leading bioconvergence company,with three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.

Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people's health and lives.

Our products are trusted by more than 3,500 laboratories, including the top 20 pharmaceutical companies. We have more than 32,000 instruments in the field in over 65 countries and have been cited in over 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com.



Volmerstraße 7b

D-12489 Berlin

Phone: +49 (0)30 - 6392 1700



PR Contact

Almut Gebhard

Phone +49 (0)30 - 6120 1081

Mobile +49 (0)174 3017754

Email scienion@almutgebhard.de


BICO Group AB published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 16:56:03 UTC.

ę Publicnow 2022
All news about BICO GROUP AB (PUBL)
09/14BICO : Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Su..
08/31PRESS RELEASE : New L version of the I.DOT: Now Available
08/24TRANSCRIPT : BICO Group AB, Q2 2022 Earnings Call, Aug 24, 2022
08/24TRANSCRIPT : BICO Group AB, Q2 2022 Earnings Call, Aug 24, 2022
08/24Publication of Interim Report January – June 2022
08/24BICO Group AB Reports Earnings Results for the Second Quarter and Six Months Ended June..
08/18BICO : CELLINK to establish a Centre of Excellence in India with The Indian Institute of S..
08/17Invitation to presentation of BICO's Q2 results 2022
07/28BICO : SCIENION announces expansion in the UK with the opening of new R&D and manufacturin..
07/18TRANSCRIPT : BICO Group AB, Q2 2022 Earnings Call, Jul 18, 2022
More news
Sales 2022 2 154 M 191 M 191 M
Net income 2022 -29,5 M -2,62 M -2,62 M
Net Debt 2022 362 M 32,2 M 32,2 M
P/E ratio 2022 25,7x
Yield 2022 -
Capitalization 1 764 M 157 M 157 M
EV / Sales 2022 0,99x
EV / Sales 2023 0,87x
Nbr of Employees 1 268
Free-Float 68,3%
Duration : Period :
BICO Group AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BICO GROUP AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 1
Last Close Price 27,52 SEK
Average target price 150,00 SEK
Spread / Average Target 445%
EPS Revisions
Managers and Directors
Erik Paul Gatenholm President, Chief Executive Officer & Director
Mikael Erik Engblom Chief Financial Officer
Carsten Nils Erik Browall Chairman
Hector Daniel Martinez Avila Chief Technology Officer & Executive VP
Bengt Sj÷holm Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BICO GROUP AB (PUBL)-90.09%157